BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2026. Third Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $501 thousand, or $0.04 per basic and diluted common share, compared to income from continuing operations of $50 thousand, or $0.00 pe
